Neuropeptide Y selectively potentiates alpha1-adrenoceptor-mediated contraction through Y1 receptor subtype in rat femoral artery.
D000818:Animals; D001013:Aorta, Thoracic / Q000187:drug effects; D001120:Arginine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D005263:Femoral Artery / Q000187:drug effects*; D015870:Gene Expression; D006801:Humans; D008297:Male; D009119:Muscle Contraction / Q000187:drug effects*; D009131:Muscle, Smooth, Vascular / Q000187:drug effects; D009478:Neuropeptide Y / Q000008:administration & dosage / Q000037:antagonists & inhibitors / Q000493:pharmacokinetics*; D010656:Phenylephrine / Q000008:administration & dosage / Q000493:pharmacokinetics; D051381:Rats; D017208:Rats, Wistar; D018340:Receptors, Adrenergic, alpha-1 / Q000187:drug effects*; D017476:Receptors, Neuropeptide Y / Q000037:antagonists & inhibitors / Q000187:drug effects* / Q000235:genetics; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012701:Serotonin / Q000008:administration & dosage / Q000493:pharmacokinetics
C092926:BIBP 3226; D009478:Neuropeptide Y; D018340:Receptors, Adrenergic, alpha-1; D017476:Receptors, Neuropeptide Y; C097212:neuropeptide Y-Y1 receptor; D010656:Phenylephrine; D012701:Serotonin; D001120:Arginine